Skip to main content

Advertisement

Table 3 Main parameters and effects of of rhGH or rhGH + Anastrazole administration in the 24 adolescent males

From: A randomized pilot trial of growth hormone with anastrozole versus growth hormone alone, starting at the very end of puberty in adolescents with idiopathic short stature

  GH alone GH + Anastrazole P
N 12 12  
GH dosage (mg/k.d) 0.073 ± 0.09 0.076 ± 0.01 NS
Duration of GH administration (mo) 11.5 ± 5 19 ± 5.9 0.02
Age at end of GH (yrs) 16.2 ± 1.1 16.8 ± 0.7 0.08
Mean IGF1 (SDS) 0.55 ± 0.3 0.65 ± 0.6 NS
Delta IGF1 (SDS)* 1.02 ± 0.3 0.97 ± 0.5 NS
Predicted height**    
 cm 158.2 ± 2.9 157.9 ± 3.8 NS
 SDS - 2.84 ± 0.5 - 2.9 ± 0.6 NS
Final height    
 cm 164.2 ± 5.6 168.4 ± 2.6 0.02
 SDS - 1.8 ± 0.9 - 1.1 ± 0.4 0.02
Growth velocity Year 1 (cm/yr) 4.9 ± 4 6.7 ± 2.8 0.18
Growth velocity Year 2 (cm/yr) 1.2 ± 0.5 3.6 ± 2.7 0.008
Height increase from GH onset (HtG1) (cm) 7.8 ± 5 12.7 ± 5.6 0.02
Height gain vs PAH (HtG2) (cm) 5.9 ± 4.5 10.5 ± 5.2 0.02
  1. Values are expressed as mean ± SD.
  2. *Mean IGF1 during GH-IGF1 at onset of GH.
  3. **see Methods/Calculation.